Coronary artery disease (CAD) is a global problem that affects approximately 315 million people every year.1 In some CAD, calcified plaque limits blood flow in the larger arteries of the heart, which increases the risk of adverse side effects.
Shockwave coronary IVL disrupts coronary calcium through its unique mechanism of action (MOA), modifying calcium in a safe, effective and intuitive manner prior to stent deployment.
Shockwave Medical is the first-ever manufacturer of coronary IVL products — the most studied and frequently used calcium modification strategy10 in our field. Our commitment to clinical research, continuous innovation and meaningful physician collaboration has set a new standard of care that is shaping the future of treating calcified coronary artery disease.
This section presents key statistical information with numbers and descriptions.
Multiple clinical trials demonstrate coronary IVL’s safety, efficacy and intuitiveness within global patient populations.
DISRUPT CAD I | DISRUPT CAD II | DISRUPT CAD III | DISRUPT CAD IV | DISRUPT CAD Pooled | DISRUPT CAD Pooled OCT | |
Study design | Single arm, safety & feasibility | Single arm, post-market, safety & effectiveness | Single arm, IDE, safety & effectiveness | Single arm, pre-market, safety & effectiveness | Individual patient data (IPD) pooled analysis of the DISRUPT CAD I-IV studies | Individual patient data (IPD) pooled analysis of the DISRUPT CAD I-IV OCT sub-studies |
Number of patients | 60 | 120 | 384 | 64 | 628 | – |
Number of patients in OCT sub-study | 31 | 47 | 100 | 71 | – | 262 |
Number of sites | 7 | 15 | 47 | 8 | 72 | 72 |
Regions | AU, EU | EU | U.S., EU | Japan | AU, EU, U.S., Japan | AU, EU, U.S., Japan |
*Calcium Crush is not available in all countries, please contact your local sales representative for details.
1: Stark, B., Johnson, C., & Gregory Andrew Roth. (2024). Global Prevalence of Coronary Artery Disease: An Update from The Global Burden of Disease Study. Journal of the American College of Cardiology, 83(13), 2320-2320.
2: Généreux P, et al. JACC 2014; 63(18);1845-54.
3: Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol 2014;63:1703.
4: Chambers JW, Feldman RL, Himmelstein SI, et al. Pivotal trial to evaluate the safety and efficacy of the Orbital Atherectomy System In Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II). J Am Coll Cardiol Intv 2014;7:510-8.
5: Genereux P, Lee AC, Kim CY, et al. Orbital atherectomy for treating de novo severely calcified coronary narrowing (1-year results from the pivotal ORBIT II Trial). Am J Cardiol 2015;115: 1685-90.
6: Yamamoto MH, Maehara A, Karimi Galougahi K, et al. Mechanisms of orbital versus rotational atherectomy plaque modification in severely calcified lesions assessed by optical cohérence tomography. J Am Coll Cardiol Intv 2017;10: 2584-6.
7: Kini AS, Vengrenyuk Y, Pena J, et al. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. Catheter Cardiovasc Interv 2015;86:1024-32.
8: Ferrer Gracia MC, et al. Failure in the implantation of drug eluting stents. Frequency and related factors. Med Intensiva. 2007.
9: Mintz, G; I. J Am Coll Cardiol Imaging 2015;8(4): 461-71.
10: Neel Butala et al. „Use of Calcium Modification During Percutaneous Coronary Intervention After Introduction of Coronary Intravascular Lithotripsy“ Journal of the Society for Cardiovascular Angiography & Interventions. 2024; DOI: 10.1016/j.jscai.2023.101254.
11: Robert Riley et al. „SCAI expert consensus statement on the management of calcified coronary lesions.“ J Soc Cardiovasc Angiogr Interv. 2024.
12: Ziad Ali et al. „Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Calcified Nodules.“ JACC Cardiovasc Interv. 2023.
13: Ziad Ali et al. „Impact of Calcium Eccentricity on the Safety and Effectiveness of Coronary Intravascular Lithotripsy: Pooled Analysis From the Disrupt CAD Studies.“ Cardiovascular Interv. 2023.